FDA Accepts Viatris's Fast-Acting Meloxicam NDA, Sets December PDUFA Date
VTRS has more than doubled off its 52-week low of $8.19.
Summary
The U.S. FDA has accepted Viatris's New Drug Application (NDA) for its fast-acting meloxicam, intended for the treatment of moderate-to-severe acute pain. The agency has set a Prescription Drug User Fee Act (PDUFA) goal date of December 27, 2026, for its decision. This acceptance is a significant positive regulatory milestone, indicating the FDA has deemed the application complete and ready for review. It moves the drug closer to potential market approval and future revenue generation for Viatris. Traders will now focus on the upcoming PDUFA date as a key catalyst for the stock.
At the time of this announcement, VTRS was trading at $16.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.2B. The 52-week trading range was $8.19 to $17.53. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.